SCHEMBL17406830

SCHEMBL17406830

CC1CCN2C(=O)CCCC2C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CHRNA7 P36544 2/20 0.38
CHRNA4 P43681 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
PARP1 P09874 1/20 0.35
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
BRD4 O60885 1/20 0.33
BRD2 P25440 1/20 0.33
AKR1C3 P42330 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
GFER P55789 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21739122 0.89 RAB9A (0.34) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL21740357 0.89 RAB9A (0.34) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL19276941 0.89 RAB9A (0.34) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL4331457 0.87 BRD4 (0.36) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL27106792 0.79 KMT2A (0.42) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL27106788 0.79 KMT2A (0.42) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL25033728 0.77 TDP1 (0.43) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL25033668 0.77 TDP1 (0.40) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL2598810 0.76 NOS1 (0.50) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL31655180 0.74 KMT2A (0.38) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981968-B2 Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders NORTHWESTERN UNIVERSITY (US) 2018-05-29 US disclosed
US-9981968-B2 Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders NORTHWESTERN UNIVERSITY (US) 2018-05-29 US disclosed
US-20160002252-A1 SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS NORTHWESTERN UNIVERSITY (US) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002252-A1 SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS DPYD, TYMP, TYMS CHRNB2 4792/4885CHRNB4 4813/4885CHRNA3 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.